SOURCE: Medivation, Inc.

Medivation, Inc.

May 26, 2011 08:00 ET

Medivation Announces Webcast of MDV3100 Investor Briefing at ASCO and Corporate Presentation at Jefferies Global Healthcare Conference

SAN FRANCISCO, CA--(Marketwire - May 26, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will hold the following events in June:

  • David Hung, Medivation's president and chief executive officer, Lynn Seely, Medivation's chief medical officer, and key opinion leaders Howard I. Scher, M.D., and Neal D. Shore, M.D., FACS, will participate in a Medivation sponsored MDV3100 panel at ASCO 2011 on Saturday, June 4, 2011 at 6:15 p.m. Central Time. The discussion will focus on the rapidly changing prostate cancer landscape and where MDV3100 may fit along the treatment continuum.

  • Patrick Machado, Medivation's chief business and financial officer, will present at the Jefferies 2011 Global Healthcare Conference on Thursday, June 9, 2011 at 2:30 p.m. Eastern Time at the Grand Hyatt in New York City. During the corporate presentation, Mr. Machado will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon for Alzheimer's disease.

Live audio webcasts of the presentations will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at Replays also will be available for 30 days following the live presentations.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at